H.R. 8871 is the DME Scammer Prevention Act of 2026, an introduced House bill concerning Medicare program integrity for certain medical equipment and supplies.

Is H.R. 8871 enacted law?

No. H.R. 8871 is not enacted law. GovInfo lists it as introduced in the House, and Rep. Bean’s office says it passed the House Ways and Means Committee on May 21, 2026.

What would the DME Scammer Prevention Act change?

The bill would create a 90-day claims-submission period for applicable items and require GAO to report on technology used by Medicare Administrative Contractors to screen claims for specified items.

Why does the bill matter for healthcare compliance teams?

The bill places attention on claims timing, submission format, and screening technology, which are relevant to DME claims integrity, revenue cycle controls, and Medicare program-integrity oversight.

Does H.R. 8871 prove current Medicare screening tools are failing?

No. The bill requires a GAO review of screening technology, but it does not prove that current screening tools are failing or that the bill would reduce fraud.

Healthcare compliance

DME Fraud Bill Puts Medicare Claims Screening Under Scrutiny

H.R. 8871 would create a 90-day claims-submission period for certain Medicare DME items and require GAO to examine MAC screening technology.

💡

TL;DR:
H.R. 8871 would create a 90-day claims-submission period for certain Medicare DME items and require GAO to review MAC screening technology. The bill is not law, but it signals closer attention to claims timing, submission format, and screening outcomes.

What you need to know

The change: H.R. 8871 would create a 90-day claims-submission period for applicable items and require GAO to review MAC screening technology.
Who is affected: Healthcare compliance leaders, revenue cycle teams, DME suppliers, health system risk teams, CFOs, audit leaders, and Medicare program-integrity observers.
Why it matters: The bill appears to focus attention on claims timing, submission format, and screening technology.
What to do first: Identify whether DME claims workflows rely on paper/fax channels, delayed submission, or manual exception handling.
Key date or trigger: H.R. 8871 was introduced in the House on May 19, 2026; if enacted, it would require a GAO report by January 1, 2030. (GovInfo)

Want the full decision layer?

Paid members receive deeper analysis, early-warning signals, and scenario breakdowns on how AI and policy shifts play out in practice.

Access the PolicyEdge AI Intelligence Terminal

Abstract Medicare Part D payment traceability visual with layered data pathways and oversight grids.

Medicare Part D Payment Data Gap: What HHS OIG Could Not Trace

HHS OIG found similar net drug costs for selected Medicare Part D drugs, but different payment paths and incomplete pharmacy-level DIR traceability.

Abstract security data flows passing through evidence layers, symbolizing AI vulnerability discovery and patch traceability.

AI Vulnerability Discovery Is Outpacing Patch Workflows

Anthropic’s Project Glasswing shows AI vulnerability discovery is moving faster than validation, disclosure, patching, and evidence workflows can absorb.

Abstract regulatory intelligence visual showing AI claim pathways, evidence tracing, consent boundaries, and governance review.

FTC Cox Media Settlement: Why AI Marketing Claims Need Evidence

The FTC’s proposed Cox Media settlement shows why AI marketing claims, voice-data claims, consent claims, and targeting claims need evidence before they reach customers.

Abstract AI election governance signal lines showing source review, audit paths, and traceability in a dark intelligence grid.

AI Election Answer Governance: House Letter Presses Big AI

A House letter asks major AI companies how election-related chatbot answers are sourced, audited, labeled, and corrected before the 2026 midterms.